PCSK9, His-tag Recombinant

Only %1 left

Catalog #

71204

As low as $305 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant human PCSK9 (proprotein convertase subtilisin/kexin type 9), encompassing amino acids 31-692 (end), containing pro-PCSK9 sequence (31-152). This construct contains a C-terminal His-tag (6xHis). The recombinant protein was affinity purified.

●

Synonyms

proprotein convertase subtilisin/kexin type 9, PCSK-9, FH3, Proprotein convertase 9, Subtilisin/kexin-like protease PC9, PC9, FHCL3, NARC1, LDLCQ1, Neural apoptosis-regulated convertase 1, NARC-1, HCHOLA3, PSEC0052

●

Product Data Gallery

4-20% SDS-PAGE Coomassie Staining

PCSK9: LDLR[Biotinylated] Binding

PCSK9(His)-LDLR inhibition curves using a chemiluminescent assay (#78813-1). Representative data only; data may vary by lot.

Product Info

Storage and Usage

Citations

Species

Human

Construct

PCSK9(31-692(end)-His)

Host Species/Expression System

HEK293 cells

Purity

≥90%

Format

Aqueous buffer solution

Formulation

8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

Pro: 14 kDa; Mature: 58 kDa + glycans

Amino Acids

31–692(end)

Glycosylation

This protein runs at higher MW by SDS-PAGE due to glycosylation.

Genbank #

NM_174936

UniProt #

Q8NBP7

Tag(s)

C-terminal His-tag

Background

PCSK9 is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Storage/Stability

At least 6 months at -80°C. Avoid freeze/thaw cycles.

Assay Conditions

Assay was performed according to the PCSK9[Biotinylated]-LDLR Binding Assay Kit (BPS Bioscience, #72002) with PCSK9 coated instead and LDLR[Biotinylated] enzyme titrated instead of LDLR from 400 ng/rxn – 0.39 ng/rxn.

Instructions for Use

Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.

Applications

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

Shipping Temperature

-80°C

Notes

PCSK9 is autocleaved to the ~14 kDa prodomain (a.a. 31-152) and the ~60 kDa mature form (a.a. 153-692(end)), which run at higher apparent MW by SDS-PAGE.

Warnings

Avoid freeze/thaw cycles

Scientific Category

Cholesterol

Regulatory Status

Research Use Only